Background: The National Cancer Institute meeting of 2007 resulted in the reporting terminology for thyroid cytopathology. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) aims to standardise thyroid cytopathology reporting for cytology centres and clinicians alike. Study Objective: To compare our laboratory's performance against TBSRTC. The second aim was to determine our laboratory's atypia of undetermined significance/follicular cells of undetermined significance (AUS/FLUS) reporting rate and malignant outcomes. Our laboratory subclassifies the AUS/FLUS category into AUS/FLUS not otherwise specified (NOS) and AUS/FLUS cannot exclude malignancy. Materials: All thyroid reports were retrieved from our computerised database for the period of January 1, 2008 to March 31, 2011. Histologic correlation was obtained where available, and cases were classified according to their original diagnosis into 1 of the 6 categories of TBSRTC. Results: A total of 1,767 cases were retrieved. The categories were as follows: inadequate (n = 415; 23%), benign (n = 1,063; 60%), AUS/FLUS (n = 141; 8%) [NOS (n = 93; 5%) and cannot exclude malignancy (n = 48; 3%)] suspicious for follicular/Hürthle cell neoplasm (n = 68; 4%), suspicious for malignancy (n = 37; 2%) and malignant (n = 43; 2%). The malignant rates for the categories were as follows: -6 (26%), 0 (0%), 8 (40%), 9 (38%), 11 (42%), 15 (62.5%), and 15 (94%), respectively. Conclusion: We have shown that the AUS category carries a higher malignant rate than that of the AUS category in TBSRTC of 5-15%. We conclude that subclassifying the AUS/FLUS category into NOS and cannot exclude malignancy helps to better identify patients with an increased risk of malignancy in the AUS/FLUS cannot exclude malignancy category.

Keywords:
Fine-needle aspiration, Thyroid, Bethesda system for reporting thyroid cytopathology, Atypical cells of uncertain significance
1.
Faquin WC, Baloch ZW: Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow up according to National Cancer Institute (NCI) recommendations. Diagn Cytopathol 2010;38:731-739.
2.
Yang J, Schnadig V, Logrono R, Wasserman PG: Fine-needle aspiration of thyroid nodules: a study of 4,703 patients with histologic and clinical correlations. Cancer 2007;111:306-315.
3.
Yassa L, Cibas ES, et al: Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer Cytopathol 2007;111:508-516.
4.
Renshaw A: Should ‘atypical follicular cells' in thyroid fine-needle aspirates be subclassified? Cancer Cytopathol 2010;118:186-189.
5.
Rossi ED, et al: Diagnostic efficacy of conventional as compared to liquid-based cytology in thyroid lesions. Acta Cytol 2009;53:659-666.
6.
Jo VY, Stelow E, et al: Malignant risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2010;134:450-456.
7.
Rossi ED, Morassi F, et al: Thyroid fine needle aspiration cytology processed by ThinPrep: an additional slide decreases the number of inadequate results. Cytopathology 2010;21:102.
8.
Somma J, Schlet N: Thyroid fine needle aspiration cytology: follicular lesions and the gray zone. Acta Cytol 2010;54:123-131.
9.
Ali SZ, Cibas E: The Bethedsa System for Reporting Thyroid Cytopathology. New York, Springer, 2010.
10.
Nayar R, Ivanovic M: The indeterminate thyroid fine-needle aspiration. Cancer Cytopathol 2009;117:195-202.
11.
Baloch ZW, Cibas ES, Clarke DP, et al: The National Cancer Institute thyroid fine needle aspiration state of the science conference: a summation. Cytojournal 2008;5:6.
12.
Shi Y, Ding X, Klein M, et al: Thyroid fine needle aspiration with atypia of undetermined significance: a necessary or optional category? Cancer Cytopathol 2009;117:298-304.
13.
Ohori NP, Schoedel KE: Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the Bethesda System for Reporting Thyroid Cytopathology: sources and recommendations. Acta Cytol 2011;55:492-498.
14.
Theoharis CG, Schofield KM, Hammers L, Udelsman R, Chhieng DC: The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution. Thyroid 2009;19:1215-1223.
15.
Marchevsky AM, Walts AE, Bose S, et al: Evidence-based evaluation of the risks of malignancy predicted by thyroid fine-needle aspiration biopsies. Diagn Cytopathol 2010;38:252-259.
16.
Luu MH, Fischer AH, Pisharodi L, Owens CL: Improved preoperative definite diagnosis of papillary thyroid carcinoma in FNAs prepared with both ThinPrep and conventional smears compared with FNAs prepared with ThinPrep alone. Cancer Cytopathol 2011;119:68-73.
17.
Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch Z: The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol 2012;56:333-339.
18.
Ali SZ: Thyroid cytopathology: Bethesda and beyond. Acta Cytol 2011;55:4-12.
19.
Kim JW, Park IS, Kim BM, et al: The clinical significance of atypia in thyroid fine-needle aspiration. Eur Arch Otorhinolaryngol 2007;264:1053-1057.
20.
Haberal AN, Toru S, Ozen O, Arat Z, Bilezikci B: Diagnostic pitfalls in the evaluation of fine needle aspiration cytology of the thyroid: correlation with histopathology in 260 cases. Cytopathology 2009;20:103-108.
21.
Adeniran A, et al: BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance. Acta Cytol 2011;55:570-575.
22.
Jing X, Knoepp SM, et al: Group consensus review minimizes the diagnosis of ‘follicular lesion of undetermined significance' and improves cytohistologic concordance. Diagn Cytopathol 2012;40:1037-1042.
23.
Layfield LJ, Morton MJ, Cramer HM, Hirschowitz S: Implications of the proposed thyroid fine needle aspiration category of ‘follicular lesion of undetermined significance': a five year multi-institutional analysis. Diagn Cytopathol 2009;37:710-714.
24.
Abele JS, Levine RA: Diagnostic criteria and risk-adapted approach to indeterminate thyroid cytodiagnosis. Cancer Cytopathol 2010;118:415-422.
25.
Guo F, Hou P, Shi B: Detection of BRAF mutation on fine needle aspiration biopsy specimens. Acta Cytol 2010;54:291-295.
26.
Boonyaarunnate T, Olson M, Ali Z: ‘Suspicious for a follicular neoplasm' before and after the Bethesda System for Reporting Thyroid Cytopathology: impact of standardized terminology. Acta Cytol 2013;57:455-463.
27.
Al-Abbadi M, Shareef S, Ali J, Yousef M: Application of the Bethesda System for Reporting Thyroid Cytopathology in the Eastern Province of Saudi Arabia: phase 1 pilot retrospective analysis. Acta Cytol 2013;57:481-488.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.